# Gilead Sciences, Inc. – Consensus ‘buy’ rating and 19.0% Upside Potential

- Link: https://www.directorstalkinterviews.com/gilead-sciences-inc.consensus-buy-rating-and-19.0-upside-potential/4121152553
- Published: 2024-04-19T13:51:02+01:00
- Author: Charlotte Edwards

**Gilead Sciences, Inc.** which can be found using ticker (GILD) now have 25 market
analysts covering the stock. The analyst consensus now points to a rating of ‘buy’.
The range between the high target price and low target price is between $113.92 
and $64.96 and has a mean target at $79.65. Now with the previous closing price 
of $66.93 this would imply there is now a potential upside of 19.0%. It’s also worth
noting that there is a 50 day moving average of $72.17 and the 200 day moving average
is $76.65. The company has a market cap of 82.50B. The stock price for the company
is currently $66.16 USD

 The potential market cap would be $98,178,514,129 based on the market consensus.

The company is not paying dividends at this time.

Other points of data to note are a P/E ratio of 14.7, revenue per share of $21.73
and a 9.78% return on assets.

Gilead Sciences, Inc. is a biopharmaceutical company. The Company is engaged in 
advancing medicines to prevent and treat life-threatening diseases, including human
immunodeficiency virus (HIV), viral hepatitis and cancer. The Company offers products
in HIV, Onocolgy, Liver Disease, Vekulaery, and Other. Under HIV, it offers Biktarvy,
Complera/Eviplera, Genvoya, Odefsey, Stribild, and Truvada. Its Veklury (remdesivir)
is a nucleotide analog RNA polymerase inhibitor indicated for the treatment of coronavirus
disease 2019 (COVID-19). Under oncology it offers cell therapy containing Tecartus
and Yescarta. Under this Liver Disease consists of Chronic hepatitis C virus (HCV)(
Ledipasvir/Sofosbuvir and Sofosbuvir/Velpatasvir) and Chronic hepatitis B virus (
HBV) / hepatitis delta virus (HDV) (Vemlidy and Viread). The Company’s other products
include AmBisome and Letairis. It also operates a portfolio of small molecule inhibitors
targeting PARP1 for oncology and MK2 for inflammatory diseases.

Share on:
